These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26183981)

  • 1. Cardiovascular risk factors influence response to biological therapies in psoriasis.
    Batalla A; González-Fernández D; González-Lara L; Abalde T; Salgado-Boquete L; Queiro-Silva R; Coto E; Coto-Segura P
    J Am Acad Dermatol; 2015 Aug; 73(2):327-9. PubMed ID: 26183981
    [No Abstract]   [Full Text] [Related]  

  • 2. [Psoriasis updates].
    Boulinguez S
    Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.
    Gilbert KE; Manalo IF; Wu JJ
    J Am Acad Dermatol; 2015 Aug; 73(2):329-31. PubMed ID: 26183982
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
    Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
    J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term psoriasis treatment].
    Jullien D; Battistella M
    Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse reactions of biological therapy for psoriasis.
    Brănişteanu DE; Voicu CM; Creţu A; Dimitriu A; Luca MC; Sălăvăstru CM
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(1):38-44. PubMed ID: 25970940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab.
    Al-Mutairi N; Nour T; Al-Rqobah D
    Expert Opin Biol Ther; 2013 May; 13(5):625-9. PubMed ID: 23527597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection.
    Cassano N; Vena GA
    Int J Dermatol; 2008 Sep; 47(9):980-1. PubMed ID: 18937672
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis.
    Sigurdardottir G; Ekman AK; Ståhle M; Bivik C; Enerbäck C
    J Am Acad Dermatol; 2014 Jun; 70(6):1067-75. PubMed ID: 24656729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse events of biological therapy for psoriasis: review of the literature.
    Thielen AM; Kuenzli S; Saurat JH
    Dermatology; 2005; 211(3):209-17. PubMed ID: 16205065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic therapy for psoriasis: a brief history, II.
    Tutrone WD; Kagen MH; Barbagallo J; Weinberg JM
    Cutis; 2001 Dec; 68(6):367-72. PubMed ID: 11775769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 15. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
    Dogra S; D S K; Budamakuntla L; Srinivas CR; Khopkar U; Gupta S; Shetty N; Pratap DV; Gopal MG; Rao TN; Garg V; Sumathy TK; Saraswat A; Bhat R; Kura M; Pandey N; Shah R; Sai Krishna K; Padmaja D; Manmohan G; M S R; Barve A; Montero E
    J Am Acad Dermatol; 2015 Aug; 73(2):331-3.e1. PubMed ID: 26183983
    [No Abstract]   [Full Text] [Related]  

  • 17. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS; Horn EJ; Cather JC
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
    Yamauchi PS; Gindi V; Lowe NJ
    Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonserious infections: should there be cause for serious concerns?
    Dao KH; Herbert M; Habal N; Cush JJ
    Rheum Dis Clin North Am; 2012 Nov; 38(4):707-25. PubMed ID: 23137578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.